SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 12,600 shares, a growth of 12,500.0% from the August 15th total of 100 shares. Based on an average daily volume of 9,100 shares, the days-to-cover ratio is currently 1.4 days.

SAB Biotherapeutics Stock Performance

SAB Biotherapeutics stock opened at $0.03 on Friday. SAB Biotherapeutics has a 52-week low of $0.01 and a 52-week high of $0.19. The business has a 50-day simple moving average of $0.04 and a two-hundred day simple moving average of $0.04.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.